Carmela Benson

2.2k total citations · 1 hit paper
89 papers, 1.6k citations indexed

About

Carmela Benson is a scholar working on Psychiatry and Mental health, Social Psychology and Pharmacology. According to data from OpenAlex, Carmela Benson has authored 89 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Psychiatry and Mental health, 26 papers in Social Psychology and 24 papers in Pharmacology. Recurrent topics in Carmela Benson's work include Schizophrenia research and treatment (49 papers), Mental Health Treatment and Access (26 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). Carmela Benson is often cited by papers focused on Schizophrenia research and treatment (49 papers), Mental Health Treatment and Access (26 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). Carmela Benson collaborates with scholars based in United States, Belgium and United Kingdom. Carmela Benson's co-authors include Myoung Kim, Larry Alphs, David M. Biondi, Wing Chow, Robert H. Dworkin, Nathaniel P. Katz, Kruti Joshi, Jeremiah Trudeau, Dennis C. Turk and H. Lynn Starr and has published in prestigious journals such as The Journal of Experimental Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Carmela Benson

87 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics

2022 96 citations Christoph U. Correll, Charmi Patel et al. profile →

Peers

Countries citing papers authored by Carmela Benson

Since Specialization

Citations

This map shows the geographic impact of Carmela Benson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmela Benson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmela Benson more than expected).

Fields of papers citing papers by Carmela Benson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmela Benson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmela Benson. The network helps show where Carmela Benson may publish in the future.

Co-authorship network of co-authors of Carmela Benson

This figure shows the co-authorship network connecting the top 25 collaborators of Carmela Benson. A scholar is included among the top collaborators of Carmela Benson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmela Benson. Carmela Benson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia 2024 ·Journal of Managed Care & Specialty Pharmacy ·Chao Cai, Chris M Kozma, Charmi Patel, Carmela Benson, Ismaeel Yunusa, Pujing Zhao, (unknown), Meera Narasimhan, (unknown)	4
2	The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia 2023 ·Neuropsychiatric Disease and Treatment ·(unknown), Carmela Benson, (unknown), (unknown), Dean Najarian, (unknown), Steven Wang, Ute Richarz, Srihari Gopal, John M. Kane	20
3	Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States 2023 ·Journal of Medical Economics ·Pengxiang Li, Carmela Benson, Zhi Geng, (unknown), Charmi Patel, Jalpa A. Doshi	9
4	Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia 2023 ·Journal of Managed Care & Specialty Pharmacy ·Anirban Basu, Charmi Patel, Alex Z. Fu, (unknown), Panagiotis Mavros, Carmela Benson	1
5	Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies 2023 ·Schizophrenia ·Christoph U. Correll, Carmela Benson, Bruno Émond, Charmi Patel, Marie‐Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefèbvre, Panagiotis Mavros	11
6	Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans 2023 ·Journal of Managed Care & Specialty Pharmacy ·(unknown), Dee Lin, A. Keenan, Aditya Raju, (unknown), (unknown), Carmela Benson	2
7	Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey 2022 ·BMC Psychiatry ·Alexander Keenan, Dee Lin, Jason F. Shepherd, (unknown), Carmela Benson, Sophie Meakin	8
8	Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections 2022 ·Neuropsychiatric Disease and Treatment ·Ibrahim Turkoz, Mehmet Daskiran, H. Lynn Starr, Dean Najarian, (unknown), (unknown), Alexander Keenan, Carmela Benson, Srihari Gopal	2
9	Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia 2022 ·BMC Psychiatry ·Alex Z. Fu, Jacqueline Pesa, (unknown), Carmela Benson	17
10	Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation 2022 ·Advances in Therapy ·(unknown), (unknown), Charmi Patel, Shannon C. Grabich, Carmela Benson, (unknown), Grant H. Skrepnek	9
11	Economic burden to commercial payers of young adults with schizophrenia in Colorado 2021 ·Journal of Medical Economics ·Jacqueline Pesa, Charmi Patel, David Rotter, Eros Papademetriou, Ravi Potluri, Carmela Benson	1
12	Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia? 2019 ·Population Health Management ·Dominic Pilon, Antoine C. El Khoury, Ameur M. Manceur, Maryia Zhdanava, Carmela Benson, Patrick Lefèbvre, Jalpa A. Doshi	3
13	The Economic Burden Among Patients with Treatment Resistant Depression in US Claims Data 2018 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Allitia DiBernardo, (unknown), Carmela Benson, Johan Reutfors	1
14	Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement 2015 ·Journal of Medical Economics ·Erik Muser, Chris M Kozma, Carmela Benson, Lian Mao, H. Lynn Starr, Larry Alphs, John Fastenau	7
15	Health resource and Criminal Justice system costs for Young Clinical Trial Patients with Schizophrenia and prior Incareration by treatment failure status 2015 ·Value in Health ·Chris M Kozma, Erik Muser, Carmela Benson, Ling‐Feng Mao, H. Lynn Starr, (unknown)	1
16	Health resource use and cost analysis of Schizophrenia patients participating in a Randomized, Multicenter, Double-Blind, relapse prevention study of paliperidone palmitate 3-month formulation 2015 ·Value in Health ·Carmela Benson, Costel Chirila, James E. Graham, (unknown), Qiming Zheng, (unknown)	3
17	Baseline health resource and criminal justice system costs for clinical trial patients with schizophrenia and prior incareration 2014 ·Value in Health ·Chris M Kozma, Erik Muser, Carmela Benson	1
18	Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: A randomized, phase IIIb study 2013 ·Journal of Opioid Management ·G. Vorsanger, (unknown), Jim Xiang, Carmela Benson, Bruce L. Moskovitz, Norman Rosenthal	17
19	One, Two, or Three? Constructs of the Brief Pain Inventory Among Patients With Non-Cancer Pain in the Outpatient Setting 2013 ·Journal of Pain and Symptom Management ·Kate L. Lapane, Brian J. Quilliam, Carmela Benson, Wing Chow, Myoung Kim	39
20	Gastrointestinal events after opioid treatment in nonmalignant pain: Correlates of occurrence and impact on health-related quality of life 2013 ·Journal of Opioid Management ·Kate L. Lapane, Brian J. Quilliam, Carmela Benson, Wing Chow, Myoung Soo Kim	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact